Neogen enters its fiscal first-quarter report with something it has lacked for much of the post-3M era: momentum. Food safety growth accelerated through every quarter of fiscal 2026, animal safety climbed back from a supply-driven slump, and management closed the year by guiding fiscal 2027 revenue well above where the Street had been. The catch is that the company is choosing to spend much of that progress on R&D and commercial rebuilding, and the quarter reporting after the close on October 6 is the one management already flagged as the lightest on profit. Whether investors keep looking past that will depend on how convincingly the top line holds up.
The bar itself is modest. Analysts expect earnings of $0.04 a share, double the $0.02 from a year ago, on revenue of about $208.1 million, essentially flat against $209.2 million last year. The whisper number of $0.06 sits a couple of pennies above consensus, a small gap in absolute terms but a meaningful one on such a low base, suggesting some traders expect the company's cost discipline to show through even as spending rises. On revenue, the Street has settled right at the midpoint of management's $207 million to $209 million range, having moved up from about $205.5 million once the guide was issued. That leaves little room for a surprise from simply landing inside guidance, so the composition of the number matters more than the headline.
The most important figure will be food safety core growth. It moved from a decline of 1.7% early in fiscal 2026 to 5.8% in the fourth quarter, the best since the 3M deal, and management attributed the improvement to better execution, healthier food producer volumes and a new solutions-based selling approach under a new chief commercial officer. Holding growth in that mid-single-digit zone would validate the idea that the turnaround has shifted to offense. A slide back toward low single digits would instead lend weight to management's own caution that customers are still wrestling with inflationary pressure tied to the Iran war. In animal safety, the question is whether the fourth quarter's return to slightly positive core growth was a real recovery or just a rebound from disrupted supply; continued sequential stability, with a modest lift from new screwworm treatments, would confirm the former.
Margins are where the report could look worse than the story. Management guided first-quarter adjusted EBITDA to roughly $37 million, a touch below where analysts had been, as R&D climbs about 50% for the year and commercial investments come ahead of efficiency savings. Investors should watch whether adjusted gross margin, which reached 49.7% last quarter, holds near that level, since that would show the manufacturing and sample-collection fixes are durable even while operating expenses rise. Free cash flow, which built to $26 million in the fourth quarter, and further inventory reduction are useful checks on operational health. Updates on the Petri film manufacturing transition, set to begin in November after its hardest product was validated, and on the genomics sale, now in second-phase review in Australia and New Zealand, will shape the deleveraging narrative toward roughly 2.5 times leverage.
The market has already bought in. Shares have jumped 31.1% since the last report against a 4.8% gain for the S&P 500, trade far above the 200-day average near $9.83, and at $13.76 sit a few percent below the post-earnings high of $14.26. Bullish sentiment has more than doubled from the prior quarter. That kind of rerating means a clean in-line quarter may not be enough to extend the move.
Ultimately, this report is about whether Neogen can show that its revenue acceleration is durable enough to justify a year of flat profit. Steady food safety growth, a firm reaffirmation of the $880 million to $885 million annual outlook and gross margins that hold would keep the offense narrative intact. Any wobble in core growth would make the reinvestment look much less like confidence and much more like cost.